Abstract
Mammals appear to have evolved two types of automatic defence for recognition of microbial invaders. The first type comprises a large variety of cellular receptors on leukocyte surfaces that specifically recognise microbial components such as β-glucans (Czop and Kay, 1991) and lipopolysaccharides (Lynn and Golenbock, 1992). Ligation of such a receptor triggers activation of that leukocyte usually involving cytokine release. The second type comprises a set of humoral proteins functioning as an enzymic cascade and collectively known as the alternative complement pathway (ACP). The ACP effectively acts as an immune surveillance that recognises almost any nonself surface, especially if it contains carbohydrate or glycoprotein. The ACP is activated by the nonself material, which becomes tagged or opsonised by covalent attachment of a cleavage fragment of the complement protein C3. This C3 fragment is then specifically recognised and ligated by one of five different types of surface receptor on many types of leukocyte, which are activated again usually with cytokine release. Gamma inulin is a potent and specific activator of the ACP.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
Preview
Unable to display preview. Download preview PDF.
References
Arvieux, J., Yssel, H. and Colomb, M.G., 1988, Antigen-bound C3b and C4b enhance antigen-presenting cell function in activation of T-cell clones, Immunol. 65:229
Bitter-Suermann, D. and Burger, R., 1989, C3 deficiencies, in: “The Third Component of Complement”, Current Topics in Microbiology and Immunology, J.D. Lambris, ed., Springer-Verlag, Berlin
British Pharmaceutical Codex,1979, 11th ed The Pharmaceutical Press, London
Cooper, P.D ., 1993, Solid phase activators of the alternative pathway of complement, in: “Activators and Inhibitors of Complement”, R.B. Sim, ed., Kluwer Academic Publishers, Dordrecht
Cooper, P.D ., 1995, Vaccine adjuvants based on gamma inulin, in :“Vaccine Design: the subunit and Adjuvant Approach”, M.F. Powell and M.J. Newman, eds., Pharmaceutical Biotechnology Series, Plenum Publishing Corp., N.Y., in press
Cooper, P.D. and Carter, M., 1986, Anticomplementary action of polymorphic ‘solubility forms’ of particulate inulin, Molec.Immunol. 23:895
Cooper, P.D., McComb, C. and Steele, E.J., 1991, The adjuvanticity of Algammulin, a new vaccine adjuvant, Vaccine, 9:408
Cooper, P.D. and Steele, E.J., 1988, The adjuvanticity of gamma inulin, Immunol. Cell Biol., 66:345
Cooper, P.D. and Steele, E.J., 1991, Algammulin, a new vaccine adjuvant comprising gamma inulin particles containing alum: preparation and properties, Vaccine9:351
Cooper, P.D., Turner, R. and McGovern, J., 1991, Algammulin (gamma inulin/alum hybrid adjuvant) has greater adjuvanticity than alum for hepatitis B surface antigen in mice. Immunol.Letters, 27:131
Cooper, P.D., Steele, E.J., McComb, C., McGovern, J., and Turner, R., 1993, Gamma inulin and Algammulin: two new vaccine adjuvants, in: “Vaccines 93. Modern Approaches to New Vaccines Including Prevention of AIDS”, H.S. Ginsberg, F. Brown, R.M. Chanock, and R.A. Lerner, eds., Cold Spring Harbor Laboratory Press, Cold Spring Harbor, New York
Cox, J.C., and Coulter, A.R., 1992, Advances in adjuvant technology and application, in: “Animal Parasite Control Utilizing Biotechnology”, W.K. Yong, ed., CRC Press, Boca Raton
Czop, J.K., Fearon, D.T. and Austen, K.F., 1978, Membrane sialic acid on target particles modulates their phagocytosis by a trypsin-sensitive mechanism on human monocytes, Proc.Nat.Acad.Sci., 75:3831
Czop, J.K. and Kay, J., 1991, Isolation and characterization of beta-glucan receptors on human mononuclear phagocytes, J.Exp.Med., 173:1511
Erdei, A., Spaeth, E., Alsenz, J., Rude, E., Schultz, T., Gergely, J. and Dierich, M.P., 1984, Role of C3b receptors in the enhancement of interleukin-2-dependent T-cell proliferation, Mol.Immunol., 21:1215
Erdei, A., Füst, G. and Gergely, J., 1991, The role of C3 in the immune response, Immunol.Today, 12:332
Erdei, A., Köler, V., Schäfer, H. and Burger, R., 1992, Macrophage-bound C3 fragments as adhesion molecules modulate presentation of exogenous antigens, Immunobiol. 185:314
Götze, O. and Miiller-Eberhard, H.J., 1971, The C3 activation system: an alternative pathway of complement activation, J.Exp,Med. 134:90S
Hakim, R.M ., 1986, Clinical sequelae of complement activation in hemodialysis, Clin. Nephrol., 26 suppl.1, s9
Hakim, R.M., Breillatt, J., Lazarus, J.M. and Port, F.K., 1984, Complement activation and hypersensitivity reactions to dialysis membranes, N.Engl.J.Med. 311:878
Hebell, T., Ahearn, J.M., and Fearon, D.T., 1991, Suppression of the immune response by a soluble complement receptor of B lymphocytes, Science, 254:102
Heyman, B., Wiersma, E.J. and Kinoshita, T., 1990, In vivo inhibition of the antibody response by a complement receptor-specific monoclonal antibody, J.Exp.Med. 172:665
Hollinger, F.B., 1989, Factors influencing the immune response to hepatitis B vaccine, booster dose guidelines and vaccine protocol recommendations, Am.J. Med., 87 suppl. 3A, 36s
Johnson, E., Eskeland, T. and Bertheussen, K., 1984, Phagocytosis by human monocytes of particles activating the alternative pathway of complement, Scand.J.Immunol., 19:31
Jones, G.L., Spencer, L., Lord, R., Mollard, R., Pye, D. and Saul, L., 1990, Peptide vaccines derived from a malarial surface antigen: effects of dose and adjuvants on immunogenicity, Immunol.Letters, 24:253
Klaus, G.G.B., and Humphrey, J.H., 1986, A re-evaluation of the role of C3 in B-cell activation, Immunol.Today, 7:163
Kyme, H.J., Cooper, P.D., Deol, H.S., Palmer, D.G., Dunsmore, T. and Carnegie, P.R., 1990, In vitro assessment of a new alum-poly saccharide adjuvant (Algammulin) with a defined recombinant antigen against a sheep parasite, Australian Soc. Immunol.Abstr., Melbourne
Lachmann, P.J., 1979, Complement, in: “The Antigens”, vol 5, M. Sela, ed., Academic Press, New York
Lambris, J.D., 1988, The multifunctional role of C3, the third component of complement, Immunol.Today, 9:387
Lynn W.A. and Golenbock, D.T., 1992, Lipopolysaccharide antagonists, Immunol.Today, 13:271
McDonald, E.J ., 1946, The polyfructosans and difructose anhydrides, Adv. Carbohyd. Chem., 2:253
Melchers, F., Erdei, A., Schulz, T. and Dierich, M.P., 1985, Growth control of activated, synchronized murine B cells by the C3d fragment of human complement, Nature, 317:264
Müller-Eberhard, H.J., 1981, The human complement protein C3: its unusual functional and structural versatility in host defense and inflammation, in: “Advances in Immunopathology”, W.O. Weigle, ed., Symp. Specialists Inc., Miami
Müller-Eberhard, H.J., 1988, Molecular organization and function of the complement system, Ann.Rev.Biochem. 57:321
Müller-Eberhard, H.J. and Schreiber, R.D., 1980, Molecular biology and chemistry of the alternative pathway of complement, Adv.Immunol., 29:1
Nissenson, A.R., Rice, L.E., Potter, E.V., Quintanilla, A., Shaughnessy, M.A. and Levin, M., 1979, Variations in serum complement following inulin infusion in man, Nephron, 23:218
Palmer, D.G., Cooper, P.D., Carnegie, P.R., Wallace, H., Deol, H.S., Thompson, R.C.A. and Dunsmore, T., 1990, A new polysaccharide adjuvant (Algammulin) useful for the improvement of cell-mediated immune responses in sheep,Australian Soc. Parasitol., Abstr., Fremantle
Ross, G.D. and Medof, M.E., 1985, Membrane complement receptors specific for bound fragments of C3, Adv.Immunol. 37: 217
Saul, A., Lord, R., Jones, G.L., and Spencer, L., 1992,- Protective immunization with invariant peptides of the Plasmodium falciparum antigen MSA2, J. Immunol., 148:208
Thyphronitis, G., Kinoshita, T., Inoue, K., Schweinle, J.E., Tsokos, G.C., Metcalf, E.S., Finkelman, F.D. and Balow, J.E., 1991, Modulation of mouse complement receptors 1 and 2 suppresses antibody response in vivo, JJmmunol., 147:224
Verroust, P.J., Wilson, C.B. and Dixon, F.J., 1974, Lack of nephritogenicity of systemic activation of the alternate complement pathway, Kidney Int., 6:157
Wiersma, E.J., Kinoshita, T. and Heyman, B., 1991, Inhibition of immunological memory and T-independent humoral responses by monoclonal antibodies specific for murine complement receptors, Eur.J.Immunol. 21:2501
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1995 Plenum Press, New York
About this chapter
Cite this chapter
Cooper, P.D. (1995). Vaccine Adjuvants Based On Gamma Inulin. In: Gregoriadis, G., McCormack, B., Allison, A.C. (eds) Vaccines. Nato Science Series, vol 282. Springer, Boston, MA. https://doi.org/10.1007/978-1-4613-0357-2_4
Download citation
DOI: https://doi.org/10.1007/978-1-4613-0357-2_4
Publisher Name: Springer, Boston, MA
Print ISBN: 978-1-4613-8014-6
Online ISBN: 978-1-4613-0357-2
eBook Packages: Springer Book Archive